Physician profile
Robert G Maul
NPI 1285671891
$2,636.10
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $293 · 2021: $830 · 2022: $885 · 2023: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $422.59 | 2019-2023 | Farxiga, Fasenra |
| Novo Nordisk INC | $375.33 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $345.66 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.01 | 2020-2023 | Jardiance |
| Amarin Pharma, INC. | $161.34 | 2019-2022 | |
| Abbvie INC. | $145.29 | 2019-2022 | |
| Pfizer INC. | $129.74 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $94.62 | 2019-2022 | |
| Amgen INC. | $85.63 | 2019-2022 | |
| Lilly USA, LLC | $81.26 | 2021-2022 | |
| Esperion Therapeutics, INC. | $80.48 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.17 | 2021-2022 | |
| Genentech USA, INC. | $58.03 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $57.57 | 2021 | |
| Abbott Laboratories | $52.18 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.12 | 2023 | Cologuard Collection Kit |
| Upsher-Smith Laboratories LLC | $35.37 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.73 | 2022 | |
| Si-Bone, INC. | $24.59 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $19.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $17.63 | 2021 | |
| Acclarent, INC | $17.39 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.16 | 2022 | |
| Aytu Biopharma, INC. | $15.55 | 2019 | |
| Alfasigma USA, INC. | $15.33 | 2021 | |
| Astellas Pharma US INC | $14.89 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.96 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.34 | 2019 | |
| Vivus LLC | $12.91 | 2021 | |
| Allergan, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Maul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.